Abstract
Erdheim-Chester disease is a rare histiocytic neoplasm with a wide range of clinical manifestations. Due to its rarity and protean characteristics, this condition often presents a diagnostic challenge. A Caucasian woman in her late 60s presented with unsteadiness, dysphagia and dysarthria. She was initially diagnosed with secondary progressive multiple sclerosis but deteriorated over 2 years with a potential lack of therapeutic response. Subsequent investigations resulted in the diagnosis of Erdheim-Chester disease. She received targeted therapy with BRAF and MAPK-pathway inhibitors. Her initial response to treatment has been positive with functional gains and reduced disease burden on MR brain imaging, and with no significant adverse effects.
Subject
Neurology (clinical),General Medicine
Reference12 articles.
1. Erdheim-Chester disease: consensus recommendations for evaluation, diagnosis, and treatment in the molecular era;Goyal;Blood,2020
2. Swerdlow SH . International Agency For Research On Cancer; WHO classification of tumours of haematopoietic and lymphoid tissues, . 2017 Available: http://publications.iarc.fr/Book-And-Report-Series/Who-Iarc-Classification-Of-Tumours/Who-Classification-Of-Tumours-Of-Haematopoietic-And-Lymphoid-Tissues-2017
3. The clinical spectrum of Erdheim-Chester disease: an observational cohort study
4. Misdiagnosis of multiple sclerosis;Solomon;Neurology,2019
5. The tension between early diagnosis and Misdiagnosis of multiple sclerosis;Solomon;Nat Rev Neurol,2017